Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

NCT02968901 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: macitentan
DRUG: tadalafil

Sponsor

Actelion